| Robert Goldstein, MD | |
|
5400 Gibson Se, Albuquerque, NM 87108 | |
| (505) 262-7000 | |
| Not Available |
| Full Name | Robert Goldstein |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 5400 Gibson Se, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598788606 | NPI | - | NPPES |
| 13540 | Medicaid | NM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 77168 (New Mexico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Robert Goldstein, MD Po Box 27829, Albuquerque, NM 87125 Ph: (505) 232-1920 | Robert Goldstein, MD 5400 Gibson Se, Albuquerque, NM 87108 Ph: (505) 262-7000 |
News Archive
Using novel computational and biochemical approaches, scientists have accurately designed and built from scratch 10 large protein icosahedra-polyhedra with 20 faces-similar to viral capsids that carry viral DNA.
Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, announces today that it has granted an aggregate of 175,000 stock options at an exercise price of $0.15 per common share, to the President & CEO of the Company.
Scientists from A*STAR's Singapore Immunology Network (SIgN) and the University of Milano-Bicocca, Italy, have discovered another signaling pathway for the activation and apoptosis, or programmed cell death, of dendritic cells. This discovery was published in the advanced online publication of Nature on 15 Jun 2009.
Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the US Food and Drug Administration (FDA) for its Famotidine for Oral Suspension (40 mg / 5 mL). Commercial shipments of the product have already commenced.
The nation's fourth leading cause of death, chronic obstructive pulmonary disease (COPD), is now being measured by the Minnesota Department of Health's Environmental Public Health Tracking Program. The program focuses on three major causes of hospitalizations in Minnesota that can be triggered or made worse by environmental factors such as secondhand smoke or outdoor air pollution — asthma, heart attacks and COPD.
› Verified 9 days ago
Dr. Alberto Aguayo Rico, M.D, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 401 San Mateo Blvd Se, Albuquerque, NM 87108 Phone: 505-462-7333 Fax: 505-462-7440 | |
Peter Guido, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 4700 Jefferson St Ne, Ste 800, Albuquerque, NM 87109 Phone: 505-872-6000 Fax: 505-872-6003 | |
Kenneth A Bell, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2901 Transport St Se, Albuquerque, NM 87106 Phone: 505-262-7110 Fax: 505-262-7308 | |
Joseph F. Oser, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1501 San Pedro Dr Se, Albuquerque, NM 87108 Phone: 505-265-1711 | |
Dr. Stanley Zissman Berman, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 7416 Vista Del Arroyo Ave Ne, Albuquerque, NM 87109 Phone: 505-884-7270 | |
Huyentrang Vu, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: Unm Hospital Internal Medicine, 2211 Lomas Blvd Ne, Albuquerque, NM 87131 Phone: 505-272-6225 | |
Tamara Goodman, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 4901 Lang Ave Ne, Albuquerque, NM 87109 Phone: 505-842-8171 |